

For Immediate Release

**9th Advanced GMP Workshop 2024, organized by IPA:
India aspires to be global benchmark in Quality & Manufacturing excellence**

Mumbai, 26th October 2024: Reinforcing its commitment to global manufacturing excellence, Indian Pharmaceutical Alliance (IPA) convened the 9th Advanced Good Manufacturing Practices (GMP) Workshop. The two-day workshop held virtually featured over **25 distinguished industry leaders, subject matter experts, and global regulators, including USFDA and CDSCO.**

The workshop was attended by over **2,500 professionals including CXOs of pharma industry, academia, and leaders from WHO, USFDA, CDSCO, IGBA, PDA, USP, and other industry associations.** The workshop featured sessions covering pertinent topics and future trends, including **strategies for addressing inspection outcomes, operational excellence, quality assurance in BA/BE studies, driving regulatory harmonization, enhancing data governance and sustainability.**

The workshop commenced with a welcome address by **Mr Sudarshan Jain**, Secretary General, IPA, followed by remarks from notable industry figures, including **Mr Nilesh Gupta**, Chair, Quality Forum, IPA & Managing Director, Lupin, **Mr Gregory Smith**, Country Director, India Office, Office of Global Operations, USFDA, and Keynote Address by **Dr Rajeev Raghuvanshi**, Drugs Controller General of India, CDSCO, Government of India.

Dr Rajeev Raghuvanshi, Drugs Controller General of India, CDSCO, Government of India, said, *"At the heart of the pharmaceutical industry lies one unwavering principle: Quality. It's not just a goal; it is the foundation of our global leadership, and the trust placed in us. The world is increasingly looking towards India, not just for our contributions to generic medicines, but for our growing leadership in advanced areas like biologics, medical devices, and digital health."*

Mr. Nilesh Gupta, Chair, Quality Forum, IPA & Managing Director, Lupin, said, *"Our industry's reputation, and more importantly, the trust of millions of patients worldwide, are built on the cornerstone of quality. It is encouraging to see that the Indian pharmaceutical sector is making significant strides towards becoming a global benchmark for quality through capability building, process improvements, talent development, digitalization, and fostering a quality-first mindset."*

Mr Sudarshan Jain, Secretary General, IPA, said, *"The 9th Advanced GMP Workshop has provided a platform for collaboration, equipping industry leaders and regulators with the tools and insights necessary to meet the highest international standards. IPA leadership is committed to strengthening operational capabilities and ensuring that patients worldwide have access to affordable and quality assured medicines."*

IPA also announced the dates of the flagship pharma event of the year - the 10th Global Pharmaceutical Quality Summit, which will be organized on 27 & 28 February 2025 in Mumbai.

About IPA:

IPA represents 23 research-based national pharmaceutical companies. Collectively, IPA companies account for over 85 percent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country's exports of drugs and pharmaceuticals and service over 64 percent of the domestic market. For more information, visit <https://www.ipa-india.org/>

For further information, please contact AVIAN WE:

Aniket Singh | 9560476715 | aniket@avianwe.com

Nisha Boruah | 7836911132 | nishab@avianwe.com